Open AccessPulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report
Author(s) -
Л. М. Макеева,
Е. И. Емелина,
G. E. Gendlin,
И. Г. Никитин,
Yu. A. Vasyuk,
V V Nesvetov
Publication year - 2017
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2428
Subject(s) - dasatinib , cardiotoxicity , medicine , myeloid leukemia , heart failure , cardiology , tyrosine kinase inhibitor , imatinib , intensive care medicine , chemotherapy , cancer
Modern treatment of patients with oncohematological diseases has allowed to achieve remission or even convalescence in many cases. One of ambitious aims put forward by the hematological society is 100% survival and preservation of quality of life in patients with chronic myeloid leukemia (CML). This hope is related with the emergence of targeted therapy for CML. The second-generation tyrosine kinase inhibitor, dasatinib, which is used for treatment of CML, can occasionally induce severe pulmonary hypertension (PH). We presented here a case report of such cardiotoxicity, which was evident as PH and heart failure in a young female patient with CML treated with dasatinib. Information from published reports about this type of cardiotoxicity is provided. At present time, dasatinib is beginning to be extensively used also in other oncological diseases. For this reason, cardiologists and physicians should be aware of this cardiotoxicity, which can cause heart failure in dasatinib-treated patients.